Sociedad Americana de Hirudoterapia

Destabilase-lysozyme of medicinal leech. Multifunctionality of recombinant protein

Basic science published in Biochem Mosc (2010)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: In vitro / laboratoryDesarrollo de fármacosResistencia antimicrobianaGenómica y proteómicaZavalova LL et al. · Biochemistry (Mosc), 2010

Abstract

Preparation and purification of a recombinant protein are described along with characteristics of its specific (for ε-(γ-Glu)-Lys and D-dimer substrates) and nonspecific (for L-γ-Glu-pNA) isopeptidase activities; the absence of peptidase function for α-(α-Glu)-Lys substrate is noted. It is shown that the protein exhibits muramidase (cell walls of Micrococcus lysodeikticus) and specific glycosidase activities. The latter was determined towards the fluorogenic substrate 4-methylumbelliferyl-tetra-N-acetyl-β-chitotetraoxide. Antimicrobial activity of recombinant destabilase-lysozyme protein (recDest-Lys) and its 11-membered amphipathic peptide was revealed towards cells of the strict anaerobic Archaean Methanosarcina barkeri, whose cell walls contain no murein. Possible mechanisms of the effect of recDest-Lys on these cells are discussed.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsAnti-Infective AgentsEndopeptidasesFluorescent DyesLeechesMicroscopy, Electron, TransmissionMuramidaseRecombinant ProteinsSubstrate Specificity

Resumen

Recombinant destabilase-lysozyme exhibits muramidase, isopeptidase and antimicrobial activity against M. barkeri.

Por qué esto importa para la hirudoterapia

This study describes the preparation and functional characterization of a recombinant destabilase-lysozyme protein derived

Citación

Destabilase-lysozyme of medicinal leech. Multifunctionality of recombinant protein.

Zavalova LL et al. · Biochemistry (Mosc), 2010

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.